Free tool
FAERS Monitor: Lyumjev
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761109 or its brand name (Lyumjev, Insulin Lispro-Aabc). Reports on generic versions are filed under their own applications.
Reports
2,106
Serious
454
22% of reports
Hospitalization
183
Death reported
35
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased566
- infusion site pain266
- drug ineffective224
- injection site pain224
- wrong technique in product usage process160
- incorrect dose administered148
- blood glucose decreased103
- product dose omission issue71
- visual impairment63
- haemorrhage57
- blood glucose abnormal56
- accidental underdose55
- infusion site erythema53
- nausea51
- glycosylated haemoglobin increased46
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 78 |
| 2021 | 372 |
| 2022 | 393 |
| 2023 | 340 |
| 2024 | 342 |
| 2025 | 383 |
| 2026 | 194 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,053 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion site painSignal | 266 | 210.5 | 187.8 | 54,137 |
| infusion site erythemaSignal | 53 | 63.2 | 48.4 | 3,163 |
| accidental underdoseSignal | 55 | 38.3 | 29.5 | 1,955 |
| blood glucose abnormalSignal | 56 | 30.4 | 23.4 | 1,558 |
| blood glucose increasedSignal | 566 | 30.1 | 28.0 | 15,984 |
| blood glucose decreasedSignal | 103 | 21.5 | 17.8 | 1,990 |
| glycosylated haemoglobin increasedSignal | 46 | 18.2 | 13.7 | 732 |
| wrong technique in product usage processSignal | 160 | 7.9 | 6.8 | 965 |
| injection site painSignal | 224 | 7.3 | 6.4 | 1,228 |
| incorrect dose administeredSignal | 148 | 6.5 | 5.5 | 687 |
| haemorrhageSignal | 57 | 5.4 | 4.2 | 203 |
| visual impairmentSignal | 63 | 5.1 | 4.0 | 203 |
| product dose omission issueSignal | 71 | 2.4 | 1.9 | 58 |
| drug ineffective | 224 | 1.7 | 1.5 | 68 |
| nausea | 51 | 0.6 | 0.5 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.